| Literature DB >> 35086525 |
Alicia Usategui1, Cristina Municio1, Elena G Arias-Salgado2, María Martín1, Beatriz Fernández-Varas2, Manuel J Del Rey1, Patricia Carreira1,3, Antonio González4, Gabriel Criado1, Rosario Perona2, José L Pablos5,6.
Abstract
BACKGROUND: To investigate the role of cell senescence in systemic sclerosis (SSc), we analyzed telomere shortening (TS) in SSc patients and the effect of targeting DNA damage in the bleomycin model of skin fibrosis.Entities:
Keywords: Fibroblast; Systemic sclerosis; Telomere length
Year: 2022 PMID: 35086525 PMCID: PMC8793167 DOI: 10.1186/s12979-022-00263-2
Source DB: PubMed Journal: Immun Ageing ISSN: 1742-4933 Impact factor: 6.400
Fig. 1Telomere length in SSc patients and healthy controls. A TL in bp as determined in whole blood DNA by TRF Southern blot in healthy controls (blue, n 68) and SSc patients (red, n 174) plotted against age. r indicates the TL/age correlation coefficient by Spearman rank test, SSc p = 0.0001. HC p < 0.0001. B TL z-score of healthy controls, SSc patients, and SSc clinical and serological subsets. Median and IQR [25,75%] are represented. HC: healthy controls, lcSSc: limited cutaneous SSc, dcSSc: diffuse cutaneous SSc, ILD: Interstitial lung disease, ATA+: anti-topoisomerase-I positive, ACA+: anti-centromere protein B positive, Comorb.: Comorbid conditions, NS: Non significant, *p < 0.05, ** p < 0.0001
Age adjusted TL in SSc patients and controls
| N | TL (z-score)1 | p | <Percentile 10th n (%) | p | |
|---|---|---|---|---|---|
| Healthy Controls | 68 | −0.00 [− 0.28, 0.31] | Ref | 6 (9%) | Ref |
| SSc patients | 174 | −0.84 [−1.15, − 0.62] | < 0.0001 | 71 (41%) | < 0.0001 |
| dcSSc | 69 | −0.84 [−1.93, 0.05] | < 0.0001 | 29 (42%) | < 0.0001 |
| lcSSc | 105 | −0.85 [−1,57, 0,18] | < 0.0001 | 40 (38%) | 0.0001 |
| ILD | 57 | −1.03 [− 1.63, −0.42] | < 0.0001 | 24 (41%) | < 0.0001 |
| No ILD | 117 | −0.83 [−1.62, 0.32] | 0.004 | 45 (39%) | 0.0001 |
| ATA+ | 54 | −1.04 [− 1.6, −0.03] | 0.0002 | 22 (41%) | < 0.0001 |
| ACA+ | 62 | −0,63 [−1.30, 0.47] | 0.025 | 20 (32%) | 0.0008 |
| Comorbidity2 | 115 | −0.85 [−1.58, 0.18] | 0.0001 | 44 (38%) | < 0.0001 |
| No comorbidity | 59 | −0.84 [−2.06, − 0.02] | 0.0003 | 27 (28%) | < 0.0001 |
1Median (IQR, 25–75%). 2 Comorbidity includes hypertension, hypercholesterolemia, diabetes, smoking or major adverse cardiovascular events (MACE). lcSSc: limited cutaneous SSc. dcSSc: diffuse cutaneous SSc. ILD: Interstitial lung disease. NS: Non significant. ATA+ (anti-topoisomerase-I positive), ACA+ (anti-centromeric protein B positive)
Fig. 2Effect of GSE4-nanoparticles on the development of bleomycin-induced skin fibrosis. C3H mice received daily subcutaneous injections of bleomycin, and were also injected with either scramble (Bleo + Scr) or GSE4 (Bleo + GSE4) nanoparticles every other day for 4 weeks. Control mice were daily injected with saline. A Representative image of Masson’s stained skin biopsy for each group. B Fibrosis was measured as the fold increase in the collagen Masson stained area adjusted to the normal area (saline group). Quantification of mRNA expression by quantitative RT-PCR of Acta2 (C) and Ctgf (D). *p < 0.05, **P < 0.01, ***p < 0.001 (Median and IQR, Mann-Whitney test). Graphic shows data of 3 independent experiments with 10 mice per group. Bar 50 μm
Fig. 3Effect of GSE4-lentiviral transduction to cultured dermal fibroblasts on profibrotic genes and phospho-H2A.X protein expression. Fibroblasts were transduced with scramble or GSE4 expression lentiviral vectors, and treated with TGF-β or bleomycin for 24 h as indicated. A Quantification of mRNA expression by quantitative RT-PCR of COL1A1, CTGF and ACTA2 (n = 11). (B) Representative image of Western blot analysis of phospho-H2A.X protein expression in a dermal fibroblast line (upper panel). Densitometric quantification shown as the ratio pH2A.X/β-actin (n = 10) (lower panel). *p < 0.05, **p < 0.01, ***p < 0.0001 (Median and IQR, Wilcoxon matched-pairs signed Rank Test)
Demographic and clinical characteristics of SSc patients
| Variables | SSc population ( |
|---|---|
| Age (median, IQR) | 54 (21) |
| Gender, female, n (%) | 151 (86.8) |
| Race, Caucasian, n (%) | 169 (97.1) |
| Smoking history, n (%) | 74 (42.5) |
| Comorbidities, n (%) | |
| Diabetes mellitus | 15 (8.6) |
| Hypertension | 42 (24.1) |
| Dyslipidemia | 40 (23.0) |
| MACE | 11 (6.3) |
| Cancer | 14 (8.1) |
| Disease duration1 median (IQR), years | 7 (10) |
| Disease subtype, n (%) | |
| lcSSc | 105 (60.3) |
| dcSSc | 69 (39.6) |
| Autoantibodies, n (%) | |
| ATA | 54 (31.0) |
| ACA | 62 (35.6) |
| Clinical involvement of SSc, n (%) | |
| Pulmonary hypertension | 17 (9.8) |
| Pulmonary (ILD) | 57 (32.7) |
| Cardiac | 29 (16.7) |
| Gastrointestinal | 137 (78.7) |
| Renal | 7 (4.0) |
| Previous Therapy, n (%) | |
| Glucocorticoids | 98 (56.3) |
| Immunosuppressive drugs2 | 80 (46.0) |
| Maximal mRSS ever, median (IQR), range 0–51 | 10 (19) |
| Death by any cause, n (%) | 34 (19.5) |
1From first non-Raynaud disease manifestation. 2Azathioprine, Methotrexate, Cyclophosphamide, Mycophenolate mofetil, Rituximab or Leflunomide. (ILD) Interstitial lung disease. lcSSc limited cutaneous SSc, dcSSc diffuse cutaneous SSc, ATA anti-topoisomerase I antibodies, ACA anticentromere antibodies, n number, mRSS modified Rodnan skin score. Clinical definitions are described in Additional file 1 and according to reference [25]